Short‐term safety of an anti‐severe acute respiratory syndrome coronavirus 2 messenger RNA vaccine for patients with advanced lung cancer treated with anticancer drugs: A multicenter, prospective, observational study

Short‐term safety of an anti‐severe acute respiratory syndrome coronavirus 2 messenger RNA vaccine for patients with advanced lung cancer treated with anticancer drugs: A multicenter, prospective, observational study

Abstract Background Since 2020, severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has become prevalent worldwide. In severe cases, the case fatality rate is high, and vaccine prevention is important. This study evaluated the safety of receiving SARS‐CoV‐2 vaccine in patients with advanced...

Full description

Bibliographic Details
Main Authors: Tomoki Tamura, Kiichiro Ninomiya, Toshio Kubo, Shoichi Kuyama, Sayaka Tachibana, Koji Inoue, Kenichi Chikamori, Kenichiro Kudo, Nobuaki Ochi, Daijiro Harada, Yoshinobu Maeda, Katsuyuki Kiura
Format: Article
Language:English
Published: Wiley 2022-02-01
Series:Thoracic Cancer
Subjects:
anticancer drugs
COVID‐19
lung cancer
SARS‐CoV‐2
vaccine
Online Access:https://doi.org/10.1111/1759-7714.14281

Internet

https://doi.org/10.1111/1759-7714.14281

Similar Items